Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

High-resolution mapping of mitotic DNA synthesis under conditions of replication stress in cultured cells.

Groelly FJ. et al, (2023), STAR Protoc, 4

Targeting DNA damage response pathways in cancer

Groelly FJ. et al, (2022), Nature Reviews Cancer

MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer.

Dinami R. et al, (2022), EMBO Mol Med

Mitotic DNA synthesis is caused by transcription-replication conflicts in BRCA2-deficient cells.

Groelly FJ. et al, (2022), Mol Cell

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells.

Dagg RA. et al, (2021), Nat Commun, 12

DNA Damage and Cancer Immunotherapy: a STING in the Tale.

Reisländer T. et al, (2020), Mol Cell

The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.

Tarsounas M. and Sung P., (2020), Nat Rev Mol Cell Biol

Radiolabeled Oligonucleotides Targeting the RNA Subunit of Telomerase Inhibit Telomerase and Induce DNA Damage in Telomerase-Positive Cancer Cells.

Jackson MR. et al, (2019), Cancer Res, 79, 4627 - 4637

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.

Reisländer T. et al, (2019), Nature communications, 10

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

Tacconi EM. et al, (2019), EMBO Mol Med, 11

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E. et al, (2019), Cancer Cell, 35, 950 - 952

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

Tacconi EM. et al, (2019), EMBO Mol Med

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E. et al, (2018), Cancer Cell, 33, 1078 - 1093.e12

Tc-99m-duramycin imaging reveals variable tissue toxicity of cancer drugs

Sneddon D. et al, (2018), JOURNAL OF NUCLEAR MEDICINE, 59

Corrigendum: MUS81 nuclease activity is essential for replication stress tolerance and chromosome segregation in BRCA2-deficient cells.

Lai X. et al, (2017), Nat Commun, 8

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.

Tacconi EM. et al, (2017), EMBO Mol Med, 9, 1398 - 1414

MUS81 nuclease activity is essential for replication stress tolerance and chromosome segregation in BRCA2-deficient cells.

Lai X. et al, (2017), Nat Commun, 8

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.

Schoonen PM. et al, (2017), Nat Commun, 8

Progression through mitosis promotes PARP inhibitor induced cytotoxicity in homologous recombination deficient cancer cells

Schoonen PM. et al, (2017), CANCER RESEARCH, 77

Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment.

Salvati E. et al, (2017), J Med Chem, 60, 3626 - 3635

Load More